Gastrointestinal treatments company Tranzyme Pharma (NASDAQ:TZYM) has secured $9.3 million in financing — enough to carry the company through the third quarter. Durham, North Carolina-based Tranzyme said that the loan came from an amendment and restatement of its existing debt financing facility with Oxford Finance and Horizon Technology Finance Corporation (NASDAQ:HRZN). Tranzyme will use a […]
Tranzyme Pharma (NASDAQ:TZYM) likely had hopes for an opening bounce on the day the drug development company went public, but that ball fell flat. The Research Triangle Park, North Carolina company’s stock price closed at $4 per share, the same price for the stock as when Tranzyme’s shares started trading on Monday morning. During the […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
North Carolina’s next initial public offering will be Tranzyme Pharma, which expects to begin trading April 4. The company announced the date for the offering late today after earlier revising the terms of the IPO, lowering the target stock price to $4 per share. The Durham, North Carolina drug development company had initially planned to […]
The initial public offering planned by North Carolina drug development company Tranzyme Pharma now has a price. Tranzyme expects to net proceeds of $53.8 million from an offering priced between $11 and $13 per share.
UnitedHealth Group Inc., one of the nation's largest health insurers, predicts that a majority of Americans could have diabetes or pre-diabetes by 2020, at a cost of $3.35 trillion to the health care system over the next 10 years, reports the Minneapolis/St. Paul Business Journal.